Seed Financing #2: A Strong Investment for the Future
Detechgene Successfully Completes Second Seed Financing Round and Drives the Future of Diagnostics
The Cologne-based biotechnology startup Detechgene has reached another major milestone: with the successful completion of its second seed financing round, the company has secured around €3 to €3.2 million in fresh capital to consistently pursue its vision — making laboratory diagnostics accessible to everyone: fast, mobile, and reliable.
The financing round was led by Neoteq Ventures, an experienced early-stage investor with a strong focus on technology-driven startups. Additional investors include NRW.BANK, Aquarius Invest, Meerkat Holding GmbH, as well as Campus Capital and several strategic business angels.
Beyond capital, these partners contribute valuable networks, deep industry expertise, and crucial scaling experience. Especially for deep-tech startups in early growth stages, this combination of financial backing and strategic know-how is a key success factor in turning technological innovation into market-ready solutions.
Confidence from the investor side is also strong:
“Detechgene addresses a global challenge with a solution that is fast, mobile, and precise — without compromising the quality of laboratory diagnostics,” emphasizes a representative of Neoteq Ventures.
PCR to Go: Rethinking Diagnostics
At the core of development is the “PCR to Go” platform — a mobile molecular diagnostics system that combines the accuracy of traditional PCR testing with the usability of rapid tests.
The goal is clearly defined: Detechgene aims to deliver results in under 30 minutes, eliminate the need for traditional laboratory infrastructure, and enable usage worldwide — even in regions with limited resources.
The size of the financing round is notable for a hardware- and research-intensive biotech startup. Industry experts see it as a crucial step toward achieving technological milestones, preparing regulatory pathways, executing pilot projects, and strategically preparing for market entry.
In molecular diagnostics in particular, these steps are highly capital-intensive yet essential for long-term success. The funding therefore not only enables short-term development but also lays the foundation for sustainable growth.
A Growing Trend: Decentralization of Diagnostics
Detechgene is part of a broader trend: the decentralization of diagnostics. While traditional PCR testing has historically been tied to centralized laboratories, the focus is increasingly shifting toward mobile, instantly available solutions that can be deployed directly at the point of need.
The potential of this shift is enormous: faster diagnostics can significantly improve patient outcomes, help break infection chains earlier, and reduce healthcare costs in the long term.
On the global stage, major players such as Abbott and Roche are already active in the point-of-care diagnostics space. Startups like Detechgene, however, are differentiating themselves through radical usability, flexibility, and mobility.
Christoph Labisch of Aquarius Invest highlights the significance of the development:
“Detechgene brings molecular diagnostics exactly where it is needed — quickly, accurately, and on the go.”
Reza Esmaillie, Managing Director of Detechgene, is equally optimistic about the future:
“Together with our investors, we are shaping the future of diagnostics — faster, more decentralized, and more user-friendly than ever before.”
With the newly secured capital, Detechgene plans to further advance and validate its technology, build up production capacities, and prepare for entry into both national and international markets.
In the long term, the company has the potential to play a key role in fundamentally rethinking diagnostics — moving away from centralized laboratories toward a flexible, globally accessible infrastructure.
